Table 1.
Baseline Characteristics
| ArylE activity, µmol/L/min/mL |
Total | Tertile 1 <97 |
Tertile 2 97–120 |
Tertile 3 ≥120 |
p value |
|---|---|---|---|---|---|
| Number | 299 | 100 | 99 | 100 | |
| Age, years | 57 ± 12 | 56 ± 13 | 57 ± 13 | 57 ± 12 | 0.93 |
| Male, % | 64 | 71 | 64 | 57 | 0.15 |
| Black, % | 44 | 48 | 34 | 50 | 0.04 |
| Body mass index, kg/m2 |
31 ± 7 | 31 ± 7 | 32 ± 7 | 31 ± 7 | 0.69 |
| Systolic blood pressure, mmHg |
113 ± 19 | 112 ± 18 | 112 ± 18 | 115 ± 22 | 0.42 |
| Diabetes, % | 33 | 35 | 31 | 32 | 0.81 |
| Smoking, % | 31 | 33 | 34 | 25 | 0.36 |
| Coronary artery disease, % |
40 | 40 | 46 | 35 | 0.29 |
| Creatinine clearance, mL/min |
93 ± 43 | 92 ± 46 | 94 ± 42 | 93 ± 40 | 0.92 |
| Ejection Fraction, % |
30 ± 15 | 29 ± 15 | 31 ± 16 | 31 ± 14 | 0.51 |
| Ejection Fraction ≥ 40% |
29 | 27 | 29 | 29 | 0.95 |
| B-type Natriuretic Peptide, pg/mL |
163 (57 – 564) |
233 (75 – 684) |
147 (57 – 543) |
110 (39 – 301) |
0.003 |
| ACE inhibitors or ARBs, % |
78 | 73 | 75 | 87 | 0.03 |
| Beta blockers, % |
91 | 90 | 93 | 90 | 0.72 |
| Hydralazine, % | 19 | 16 | 18 | 24 | 0.34 |
| Nitrate, % | 23 | 16 | 29 | 25 | 0.1 |
| Statins, % | 54 | 50 | 62 | 51 | 0.16 |
| High density lipoprotein cholesterol, mg/dL |
41 ± 13 | 38 ± 11 | 40 ± 13 | 46 ± 15 | <0.001 |
| Low density lipoprotein cholesterol, mg/dL |
97 ± 36 | 93 ± 38 | 96 ± 30 | 101 ± 38 | 0.33 |
Abbreviations: ArylE: Arylesterase. ACE: Angiotensin converting enzyme. ARB: Angiotensin II receptor blockers.